Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis

European Cytokine Network

Volumn 21, Issue 4, 2010, Pages 251-256

  Costantini, Susan ^a   Capone, Francesca ^a   Guerriero, Eliana ^a   Maio, Patrizia ^b   Colonna, Giovanni ^c   Castello, Giuseppe ^a  

^a Centro Ricerche Oncologiche di Mercogliano (CROM) Fiorentino Lo Vuolo   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cancer; Chemokines; Cirrhosis; Cytokines; Growth factors; HCV

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; GROWTH FACTOR; SCATTER FACTOR;

AGED; ARTICLE; BIOMETRY; CHRONIC INFLAMMATION; CLINICAL EVALUATION; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT MONITORING; PROGNOSIS; PROTEIN BLOOD LEVEL; UPREGULATION;

BIOLOGICAL MARKERS; CYTOKINES; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION MEDIATORS; LIVER CIRRHOSIS; MALE; PROGNOSIS;

HEPATITIS C VIRUS;

EID: 78650498557     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2010.0214     Document Type: Article

References (29)

1. Myrmel H, Ulvestad E, Asjø B. The hepatitis C virus enigma. APMIS 2009; 117: 427-39.
2. Walds JR. Prevention of Hepatocellular Carcinoma. N Engl J Med 2004; 351: 1567-70.
3. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946-52.
4. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-7.
5. Ueno Y, Sollano JD, Farrell GC. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 531-6.
6. Castello G, Scala S, Palmieri G, et al. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol 2010; 134: 237-50.
7. Ghany MG, Strader DB, Thomas DL, et al. Rapporto OMS 2010.
8. Abdo AA, Al Abdul Karim H, Al Fuhaid T, et al. Gastroenterology Association Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Summary of Recommendations. Ann Saudi Med 2006; 26: 261-5.
9. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. American Association for the Study of Liver Diseases. Hepatology 2009; 49: 1335-74.
10. Larrubia JR, Benito-Martínez S, Calvino M, et al. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008; 14: 7149-59.
11. Costantini S, Capone F, Guerriero E, et al. An approach for understanding the inflammation and cancer relationship. Immunol Lett 2009; 126: 91-2.
12. Capone F, Costantini S, Guerriero E, et al. Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 2010; 21: 99-104.
13. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
14. Goral V, Atayan Y, Kaplan A. Relation between pathogenesis of liver cirrhosis, hepatic encephalopathy and serum cytokine levels - what is the role of tumor necrosis factor-alpha? Journal of Chinese Clinical Medicine 2010; 5: 1-8.
15. Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology 2009; 49: 676-88.
16. Zeremski M, Dimova R, Brown Q, et al. Peripheral CXCR3- associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. Infect Dis 2009; 200: 1774-80.
17. Wald O, Pappo O, Safadi R, et al. Involvement of the CXCL12/ CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. European Journal of Immunology 2004; 34: 1164-74.
18. Zhang HY, Nanji AA, Luk JM, et al. Macrophage migration inhibitory factor expression correlates with inflammatory changes in human chronic hepatitis B infection. Liver International 2005; 25: 571-9.
19. Kimura K, Nagaki M, Nishihira J, et al. Role of Macrophage Migration Inhibitory Factor in Hepatitis B Virus-Specific Cytotoxic-T-Lymphocyte-Induced Liver Injury. Clinical And Vaccine Immunology 2006; 13: 415-9.
20. Rasi G, Serafino A, Bellis L, et al. Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2007; 13: 4986-95.
21. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Reviews 2008; 27: 85-94.
22. Tsubouchi H, Niitani Y, Hirono S, et al. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay. Hepatology 1991; 13: 1-5.
23. Sakata H, Takayama H, Sharp R, et al. Hepatocyte growth factor overexpression inducesgrowth, abnormal development, and tumor formationin transgenic mouse livers. Cell Growth Differ 1996; 7: 1513-23.
24. Yamagamim H, Moriyama M, Matsumura H, et al. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer 2002; 95: 824-34.
25. Zekri AR, Alam El-Din HM, Bahnassy AA, et al. Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin- 2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp Hepatol 2010; 9: 1.
26. Gieling RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1324-G1331.
27. Tokusashi Y, Asai K, Tamakawa S, et al. Expression of NGF in hepatocellular carcinoma cells with its receptors in non-tumor cell components. Int J Cancer 2005; 114: 39-45.
28. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The liver and portal hypertension. Philadelphia: Saunders, 1964: 50-64.
29. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. The British journal of surgery 1973; 60: 64-9.